

# PROGRAMME – DAY ONE WEDNESDAY 5 November 2025

#### **6<sup>th</sup> ANNUAL NETWORK MEETING**

Edgbaston Park Hotel & Conference Centre, University of Birmingham, UK

08:15 **Registration and refreshments** 

09:00 Welcome and Introductions

Prof Adam Cunningham, BactiVac Network Director, UK

Theme: Evolving Use of Bacterial Vaccines

Chairs: Prof Adam Cunningham

Dr Alisha Chetty

09:15 Challenges of introducing combination vaccines

Prof William Hausdorff, Lead, Public Health Vaccine Value Propositions, Center for Vaccine Innovation and Access, PATH, USA

09:45 Combination vaccines in the context of Shigella

Dr Francesca Micoli, Director, GVGH Innovation Academy, GSK Vaccines Institute for Global Health, Italy

10:15 Innovative strategies on bacterial vaccines

Prof Mariagrazia Pizza, Professor of Microbiology, Imperial College London, UK

10:45 Refreshments

Chairs: Dr Francesca Micoli Dr Fadil Bidmos

11:15 Supporting AMR Vaccine R&D

Dr Ed Buurman, Alliance Director, CARB-X, USA

11:45 WHO Bacterial Pathogen Research & Emergency Preparedness; Research & Development Roadmaps

Prof Farah Naz Qamar, Associate Dean of Research, Aga Khan University, Pakistan

12:15 Lunch

**Chair: Prof Stephen Baker** 

13:15 Oral presentations from selected poster abstracts

See Appendix 1

14:55 Group photograph Chair: Dr Jo Dean

15:05 Refreshments

15:30 Speed networking

17:00 Poster session and drinks reception

18:30 Close of day programme

19:00 Conference Dinner – Edgbaston Park Hotel

This programme is subject to change











## PROGRAMME – DAY TWO THURSDAY 6 November 2028

### **6<sup>th</sup> ANNUAL NETWORK MEETING**

THURSDAY 6 November 2025 Edgbaston Park Hotel & Conference Centre, University of Birmingham, UK

The way Marsing Development and Involve antation	
ineme: va	ccine Development and Implementation Chairs: Prof Constantino López Macías Dr Silvia Napolitano
09:00	Driving R&D towards global health equity  Dr Hani Kim, Executive Director, The RIGHT Foundation, South Korea
09:30	Using AI in healthcare to achieve universal health coverage and equity  Mr Sameer Kanwar, Director- Digital Health, AI and Med Tech, PATH, South Asia
10:00	Defining protective antigens for next generation vaccine development  Dr Galit Alter, VP Early Vaccines and Therapies, AstraZeneca, USA
10:30	Refreshments
Theme: Vac	ccine Economics Chairs: Dr Ankur Mutreja
	Dr Vega Masignani
11:00	Vaccines to tackle AMR in the context of One Health Dr Fabian Maza, Science Officer, International Centre for Antimicrobial Resistance Solutions (ICARS), Denmark
11:30	CEPI vaccine strategy to support global south, low-middle income countries  Dr Matthew Downham, Director Manufacturing & Supply Chain Networks, CEPI, UK
12:00	Enabling access to AMR products in LMICs  Dr Sheetal Ghelani, Director of Antimicrobial Resistance, Clinton Health Access Initiative, USA
12:30	Lunch & poster viewing
Regulatory Perspectives on Product Development and Registration: Workshop	
	Chair: Dr Carmen Coxon
13:45	Introduction to session – content and learning objectives  Dr Carmen Coxon, Principal Scientist, Medicines and Healthcare Products Regulatory Agency (MHRA), UK
13:50	Regulation 101: Where to find the information you need and what it means  Dr Carmen Coxon, Principal Scientist, Medicines and Healthcare Products Regulatory Agency (MHRA), UK
14.05	Regulation 101: The role of reference materials in vaccine development  Dr Arif Felek, Principal Scientist, Vaccines, Medicines and Healthcare Products Regulatory Agency (MHRA), UK
14:20	Regulation: Introducing regulation in Africa and the African Medicines Agency Dr Joanitah Atuhaire, Inspector of Drugs, National Drug Authority, Uganda and WHO TDR Clinical Research Fellow, University of Cape Town, South Africa
14:45	Regulatory support for drug development in Malaysia: clinical trials and registration Dr Zaril Harza Zakaria, Head of Investigational Product & Safety Section, National Pharmaceutical Regulatory Agency, Ministry of Health Malaysia, Malaysia
15:10	Refreshments
15:40	Audience and panel discussion
16:30	Annual Network Meeting Closing Address Prof Adam Cunningham, BactiVac Network Director, UK











#### 6<sup>th</sup> ANNUAL NETWORK MEETING

**APPENDIX 1** 

**Chair: Prof Stephen Baker** 

Venue - Edgbaston Park Hotel, Birmingham, UK

#### **WEDNESDAY 5 NOVEMBER 2025**

**Oral Presentations from Selected Poster Abstracts** 

- 13:15 Can a novel multi-epitope, serotype-independent pneumococcal vaccine confer protection against human carriage and transmission?
  - Mr Vítor dos Santos Alves, PhD Student, Butantan Institute/University of Sao Paul, Brazil
- 13:27 Targeting Toxins: Phase I Trial of a Multivalent Vaccine Against *Staphylococcus aureus* to fight antibiotic resistance
  - Dr Silvia Napolitano, Clinical Research Associate, LimmaTech Biologics AG, Switzerland
- 13:39 Capturing the public health impact of typhoid conjugate vaccine introduction on antimicrobial use in Pakistan

  Dr Mohammad Tahir Yousafzai, Assistant Professor, Aga Khan University, Pakistan
- 13:51 Vaccine-induced antibody-dependant neutrophil phagocytosis is associated with protection against paratyphoid A infection in a human challenge model

  Dr Claudia Ivette Juarez Molina, Postdoctoral Research Scientist, Oxford Vaccine Group, University of Oxford, UK
- 14:03 AntiPan: A Genome-Driven Computational Pipeline for Subunit Vaccine Discovery Against Staphylococcus aureus
  - Prof Mohamed Elhadidy, Professor of Biomedical Sciences and Director of Center for Genomics (CG), Zewail City of Science and Technology, Egypt
- 14:15 Using genetics to understand Salmonella chronic infections and vaccine design Dr Jessica Rooke, Post Doctoral Researcher, University of Queensland, Australia
- 14:27 Establishing the relative contribution of antibodies to *emm* type-specific M protein antigen in humoral immunity to *Streptococcus pyogenes* in a high burden setting

  Dr Alexander Keeley, Wellcome Clinical Research Fellow in Global Health, MRC Unit The Gambia at London School of Hygiene & Tropical Medicine, Gambia/UK
- 14:39 Evaluation of immunogenicity of a hexavalent *Neisseria meningitidis* vaccine targeted for low- and middle-income countries (LMICs) and travellers
  - Ms Safia Syeda, Director Strategy and Innovation, Techinvention Lifecare Ltd, India

This programme is subject to change







